NEW YORK (GenomeWeb) — Singapore-based Lucence Diagnostics and NovogeneAIT Genomics Singapore announced today that they have partnered to develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.
According to the partners, the tests will be designed to analyze the genetics of cancer tissue to help personalize a patient's treatment regimen and will focus on cancers prevalent in Asia. Additional terms of the deal were not disclosed.
"This partnership combines NovogeneAIT's high-quality tissue sequencing capabilities with our analytics and insights on Asian cancer targets and treatments," Lucence Founder and CEO Min-Han Tan said in a statement. "This means deeper and more meaningful interpretation for complex cancer genetics testing."
Late last year, Lucence partnered with AstraZeneca to improve access to BRCA testing for women in Singapore with ovarian cancer.
NovogeneAIT Genomics Singapore is a joint venture between Novogene and AITbiotech that operates a high-throughput NGS center in Singapore.